Hfg is an agonist able to activate GCN2; nevertheless, the preclinical studies using this drug have been directed mostly to the cancer research field (reviewed in [83]), evaluating how nutritional sensing modification can impact in cancer cell biology, and finally its therapeutic potential as an anticancer treatment. The gene discussed is EIF2AK4; the disease is cancer.